Level C· Early human research exploring benefitsCase Report / SeriesPubMed

Treatment of atrophies secondary to trilinear scleroderma en coup de sabre by autologous tissue cocktail injection.

Oh CK., Lee J., Jang BS., Kang YS., Bae YC., Kwon KS.

Case Report / Series, published in Dermatol Surg (2003) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Dermatol Surg (2003)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
12974710
DOI
10.1046/j.1524-4725.2003.29307.x

Abstract (original English)

The atrophies are left after regression of linear scleroderma "en coup de sabre." They are often irreversible and disfiguring. Several surgical techniques have been attempted to correct atrophies secondary to linear scleroderma en coup de sabre. However, the result often has proved unsatisfactory. A patient with atrophies secondary to trilinear scleroderma en coup de sabre was treated with autologous tissue cocktail injection. Autologous tissue cocktail injection provided excellent cosmetic results for the treatment of atrophies secondary to trilinear scleroderma en coup de sabre. There were no complications at the donor and recipient site in the postoperative period. Autologous tissue cocktail injection appears to be a useful method for the correction of depressed atrophy of linear scleroderma en coup de sabre.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueAdultAtrophyDermisHumansInjections, SubcutaneousMaleScleroderma, LocalizedSkinTissue Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.